ShiraTronics Announces First Implant of its Chronic Migraine System

It delivers electrical pulses tailored to disrupt migraine pain signals.

Shira Tronics Implantable Neuromodulation Device
ShiraTronics

ShiraTronics today announced the successful implantation of its Chronic Migraine System in the world's first six patients. This milestone represents a significant leap forward in neuromodulation, as the company unveils the first-ever fully implantable system for head location utilizing a minimally invasive approach.

The RELIEV-CM clinical study, conducted in partnership with leading Australian researchers, brings together a team of distinguished neurologists and pain management physicians who will oversee the study's execution and data collection. The study evaluates the performance of ShiraTronics Chronic Migraine System and establishes the foundation for future clinical studies.

The ShiraTronics system delivers precise electrical pulses tailored to disrupt migraine pain signals. The fully implantable, programmable device aims to offer patients and physicians a new and potentially more effective treatment option.

More in Implantables